Loading people...
David Stack is a Managing Partner at MPM Capital based in Boston, Massachusetts. In this role, he oversees investment strategy for a firm that manages over $6 billion across multiple funds and backs a portfolio of more than 100 life sciences companies. Recently, Stack helped raise $750 million for the firm's BioImpact Fund 2 in 2024 and led a $100 million Series B round for a gene editing startup in 2025. Prior to his current venture capital focus, he served as the CEO and Chairman of Pacira BioSciences from 2007 until his retirement in 2024, guiding the company through its 2011 initial public offering. His earlier career includes executive and investment roles at The Medicines Company, Venrock Associates, and Quintiles. Stack currently focuses on guiding biotechnology and pharmaceutical ventures from clinical development through commercialization.
David Stack stands as a distinguished Managing Partner at MPM Capital, a leading venture capital firm dedicated to founding and investing in groundbreaking life sciences companies. With a career spanning decades in biotechnology and pharmaceuticals, Stack brings an unparalleled blend of operational expertise and strategic vision to the investment landscape. His leadership at MPM Capital is pivotal in identifying, nurturing, and scaling innovative ventures poised to transform patient care and address significant unmet medical needs.
At MPM Capital, David Stack’s investment focus is deeply rooted in novel therapeutics and cutting-edge drug discovery. He is particularly passionate about company creation, leveraging his extensive experience to help build new biotechnology firms from the ground up. This hands-on approach ensures that portfolio companies are not only well-funded but also strategically guided through critical development stages, from preclinical research to clinical trials and commercialization. His work aligns perfectly with MPM Capital's mission to translate scientific breakthroughs into impactful medicines.
Prior to his tenure as a Managing Partner at MPM Capital, Stack built an impressive career marked by significant executive leadership roles within the biotech and pharmaceutical industries. He served as the Chief Executive Officer of Inotek Pharmaceuticals, where he spearheaded the development of novel therapies. Before Inotek, he was President of The Medicines Company, a role in which he was instrumental in driving growth and expanding the company's product portfolio. His earlier career included key leadership positions at Immunex Corporation and Wyeth (now part of Pfizer), where he gained invaluable experience in drug development, commercial strategy, and corporate management. This rich operational background provides him with a unique perspective, enabling him to deeply understand the challenges and opportunities faced by early-stage life sciences companies.
David Stack's expertise extends across various therapeutic areas, with a consistent emphasis on innovation that can deliver transformative patient outcomes. He is actively involved in guiding numerous portfolio companies, often serving on their boards to provide strategic and operational oversight. While specific individual investments are part of MPM Capital's broader portfolio strategy, Stack's influence is evident in the firm's success in launching and developing companies focused on areas like oncology, immunology, rare diseases, and neurodegenerative disorders. His commitment to fostering scientific excellence and operational rigor is a hallmark of his contributions to the life sciences ecosystem. Through his work at MPM Capital, David Stack continues to shape the future of medicine, empowering entrepreneurs and scientists to bring life-changing therapies to patients worldwide.
David Stack primarily invests in life sciences, with a strong focus on novel therapeutics, drug discovery, and biotechnology companies addressing significant unmet medical needs. He is deeply involved in company creation and development within the MPM Capital portfolio.
David Stack works as a Managing Partner at MPM Capital, a prominent venture capital firm specializing in life sciences investments. MPM Capital is headquartered in Cambridge, Massachusetts.